Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis

被引：0

作者：

H. J. Nielsen

I. J. Christensen

M. N. Svendsen

U. Hansen

K. Werther

N. Brünner

L. J. Petersen

J. K. Kristensen

机构：

[1] Departments of Surgical Gastroenterology,

[2] Hvidovre Hospital,undefined

[3] University of Copenhagen,undefined

[4] Hvidovre,undefined

[5] Copenhagen,undefined

[6] Denmark,undefined

[7] Fax ++ 45 3632 3760,undefined

[8] e-mail:h.j.nielsen@ofir.dk,undefined

[9] Finsen Laboratory,undefined

[10] 49 Strandboulevarden,undefined

[11] University of Copenhagen,undefined

[12] Copenhagen,undefined

[13] Denmark,undefined

[14] Fax ++ 45 3632 3760,undefined

[15] Departments of Pathology,undefined

[16] Hvidovre Hospital,undefined

[17] University of Copenhagen,undefined

[18] Hvidovre,undefined

[19] Copenhagen,undefined

[20] Denmark,undefined

[21] Fax ++ 45 3632 3760,undefined

[22] Department of Clinical Physiology,undefined

[23] Bispebjerg Hospital,undefined

[24] University of Copenhagen,undefined

[25] Copenhagen,undefined

[26] Denmark,undefined

[27] Fax ++ 45 3632 3760,undefined

[28] Departments of Dermatology,undefined

[29] Hvidovre Hospital,undefined

[30] University of Copenhagen,undefined

[31] Hvidovre,undefined

[32] Copenhagen,undefined

[33] Denmark,undefined

[34] Fax ++ 45 3632 3760,undefined

来源：

Inflammation Research | 2002年 / 51卷

关键词：

Key words: Psoriasis – VEGF – PAI-1 – ranitidine – histamine-2 receptor antagonists – angiogenesis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective and Design: An evaluation of angiogenesis related molecules during open treatment of psoriasis.¶Materials and Subjects: Plasma samples and skin biopsies from 16 patients with psoriasis and plasma samples from 13 healthy controls.¶Treatment: Ranitidine 300 mg orally twice daily for 6 months.¶Methods: Vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor-1 (PAI-1) were determined by ELISA methods in plasma collected from the patients before treatment and after 1, 3 and 6 months. Vessel counts were performed in biopsies from affected skin areas taken before treatment and after 3 and 6 months. The results were compared to simultaneous PASI scores.¶Results: Pre-treatment plasma levels of VEGF and PAI-1 were significantly elevated in patients compared with levels in healthy persons (p = 0.02 and p = 0.04, respectively). The plasma levels decreased significantly during treatment (p = 0.03 and p = 0.01, respectively), and the decrease in combined levels correlated with the decrease in PASI score. However, the vessel density in affected skin did not change during treatment.¶Conclusions: Increased pre-treatment levels of VEGF and PAI-1 and decrease during improvement of the disease suggest that the two molecules may play a role in pathogenesis of psoriasis.

引用

页码：563 / 567

页数：4

共 50 条

[1] Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis
Nielsen, HJ
Christensen, IJ
Svendsen, MN
Hansen, U
Werther, K
Brünner, N
Petersen, LJ
Kristensen, JK
INFLAMMATION RESEARCH, 2002, 51 (11) : 563 - 567
[2] Increased plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 in children with frequent asthma exacerbations
Chung, H.
Kim, S.
Kim, S.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S297 - S297
[3] Vascular endothelial growth factor and plasminogen activator inhibitor-1 in children with recurrent early wheeze
Chung, Hai Lee
Kim, So Yeon
Kim, Sang Gyung
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (06) : 1541 - 1542
[4] Hyperhomocysteinemia leads to elevated levels of plasminogen activator inhibitor-1
Kinlaw, LM
Sauls, DL
Hoffman, M
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (05) : A13 - A13
[5] The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer
Meo, S
Dittadi, R
Peloso, L
Gion, M
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (04): : 282 - 288
[6] Plasminogen activator inhibitor-1 and vascular endothelial growth factor as risk factors for early prediction of gestational diabetes
Elksne, K.
Paunina, Z.
Jurka, A.
Rezeberga, D.
Tretjakovs, P.
22ND EUROPEAN CONGRESS OF OBSTETRICS AND GYNAECOLOGY (EBCOG 2012), 2012, : 77 - 81
[7] VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) INDUCES PLASMINOGEN ACTIVATORS AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICROVASCULAR ENDOTHELIAL-CELLS
PEPPER, MS
FERRARA, N
ORCI, L
MONTESANO, R
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 181 (02) : 902 - 906
[8] Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction
Ganti, AK
Potti, A
Yegnanarayan, R
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 (02) : 80 - 84
[9] Plasminogen activator inhibitor-1 in vascular thrombosis
Westrick, Randal J.
Eitzman, Daniel T.
CURRENT DRUG TARGETS, 2007, 8 (09) : 996 - 1002
[10] Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells
Wojta, J
Kaun, C
Breuss, JM
Koshelnick, Y
Beckmann, R
Hattey, E
Mildner, M
Weninger, W
Nakamura, T
Tschachler, E
Binder, BR
LABORATORY INVESTIGATION, 1999, 79 (04) : 427 - 438

← 1 2 3 4 5 →